Leap Therapeutics (NASDAQ:LPTX) Stock Soars To New Highs: But Why?
A ray of hope shines for the sufferers of gastroesophageal junction cancer- Leap Therapeutics (NASDAQ:LPTX) has recently had a breakthrough for a treatment! They have presented initial findings from the first-line cohort of the DisTinGuish study, which is a Phase 2a clinical trial evaluating DKN-01, its anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene Ltd.’s anti-PD-1 antibody, and chemotherapy. No wonder the company’s stock soared by a whopping 105% in…